论文部分内容阅读
专利药、进口药价格昂贵一直是导致百姓看不起大病的重要原因之一。现在,这种状况迎来转机。近日,国家卫生计生委、国家发展改革委等七部门联合发布了首批国家药品谈判结果,替诺福韦酯、埃克替尼、吉非替尼3种谈判药品降价幅度分别高达67%、54%和55%。这一消息,对慢性乙肝、肺癌等疾病患者是一大利好。新医改以来,在构建公立医疗机构药品集中采购新机制过程中,各地普遍反映专利药品和独家生产药品缺乏市场
Patented medicines and expensive imported medicines have always been one of the most important reasons that cause people to look down upon serious illness. Now, this situation usher in a turning point. Recently, the State Health and Family Planning Commission, the National Development and Reform Commission and other seven departments jointly released the first batch of national drug negotiations results. Tenofovir disoproxil, imatinib, gefitinib three kinds of negotiated drugs price cuts as high as 67% 54% and 55%. The news is good for patients with chronic hepatitis B and lung cancer. Since the new medical reform, in the process of setting up a centralized procurement mechanism for medicines in public medical institutions, there has been a general reflection of the lack of market for patented drugs and exclusively manufactured drugs